{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:32:27Z","timestamp":1793424747499,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s00417-024-06485-y","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T08:01:55Z","timestamp":1712908915000},"page":"2867-2874","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Short-term outcomes of intravitreal faricimab for refractory neovascular age-related macular degeneration"],"prefix":"10.1007","volume":"262","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7165-4699","authenticated-orcid":false,"given":"Wissam","family":"Aljundi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Munteanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berthold","family":"Seitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa Din","family":"Abdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,12]]},"reference":[{"key":"6485_CR1","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X et al (2014) Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2:e106\u2013e116","journal-title":"Lancet Glob Health"},{"key":"6485_CR2","doi-asserted-by":"publisher","first-page":"5293258","DOI":"10.1155\/2017\/5293258","volume":"2017","author":"J Blasiak","year":"2017","unstructured":"Blasiak J, Piechota M, Pawlowska E et al (2017) Cellular senescence in age-related macular degeneration: can autophagy and DNA damage response play a role? Oxid Med Cell Longev 2017:5293258. https:\/\/doi.org\/10.1155\/2017\/5293258","journal-title":"Oxid Med Cell Longev"},{"key":"6485_CR3","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.3390\/ijms14022996","volume":"14","author":"J Blasiak","year":"2013","unstructured":"Blasiak J, Glowacki S, Kauppinen A, Kaarniranta K (2013) Mitochondrial and nuclear DNA damage and repair in age-related macular degeneration. Int J Mol Sci 14:2996\u20133010","journal-title":"Int J Mol Sci"},{"key":"6485_CR4","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/ICL.0b013e31821fbd3e","volume":"37","author":"KV Chalam","year":"2011","unstructured":"Chalam KV, Khetpal V, Rusovici R, Balaiya S (2011) A review: role of ultraviolet radiation in age-related macular degeneration. Eye Contact Lens 37:225\u2013232","journal-title":"Eye Contact Lens"},{"key":"6485_CR5","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.4161\/cc.24825","volume":"12","author":"OS Kozhevnikova","year":"2013","unstructured":"Kozhevnikova OS, Korbolina EE, Ershov NI, Kolosova NG (2013) Rat retinal transcriptome: effects of aging and AMD-like retinopathy. Cell Cycle 12:1745\u20131761","journal-title":"Cell Cycle"},{"key":"6485_CR6","doi-asserted-by":"publisher","first-page":"3632169","DOI":"10.1155\/2019\/3632169","volume":"2019","author":"S Wang","year":"2019","unstructured":"Wang S, Wang X, Cheng Y et al (2019) Autophagy dysfunction, cellular senescence, and abnormal immune-inflammatory responses in AMD: from mechanisms to therapeutic potential. Oxid Med Cell Longev 2019:3632169. https:\/\/doi.org\/10.1155\/2019\/3632169","journal-title":"Oxid Med Cell Longev"},{"key":"6485_CR7","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.2165\/00003495-200868080-00002","volume":"68","author":"AV Chappelow","year":"2008","unstructured":"Chappelow AV, Kaiser PK (2008) Neovascular age-related macular degeneration: potential therapies. Drugs 68:1029\u20131036","journal-title":"Drugs"},{"key":"6485_CR8","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/eye.2015.48","volume":"29","author":"WM Amoaku","year":"2015","unstructured":"Amoaku WM, Chakravarthy U, Gale R et al (2015) Defining response to anti-VEGF therapies in neovascular AMD. Eye 29:721\u2013731","journal-title":"Eye"},{"key":"6485_CR9","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41433-019-0670-1","volume":"34","author":"A Sharma","year":"2020","unstructured":"Sharma A, Kumar N, Kuppermann BD et al (2020) Faricimab: expanding horizon beyond VEGF. Eye 34:802\u2013804","journal-title":"Eye"},{"key":"6485_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11892-016-0816-5","volume":"16","author":"PA Campochiaro","year":"2016","unstructured":"Campochiaro PA, Peters KG (2016) Targeting Tie2 for treatment of diabetic retinopathy and diabetic macular edema. Curr Diab Rep 16:1\u201311","journal-title":"Curr Diab Rep"},{"key":"6485_CR11","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/MOH.0000000000000361","volume":"24","author":"SM Parikh","year":"2017","unstructured":"Parikh SM (2017) The Angiopoietins and Tie2 in Vascular Inflammation. Curr Opin Hematol 24:432","journal-title":"Curr Opin Hematol"},{"key":"6485_CR12","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/nrd.2016.278","volume":"16","author":"P Saharinen","year":"2017","unstructured":"Saharinen P, Eklund L, Alitalo K (2017) Therapeutic targeting of the angiopoietin\u2013TIE pathway. Nat Rev Drug Discov 16:635\u2013661","journal-title":"Nat Rev Drug Discov"},{"key":"6485_CR13","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/nrc2894","volume":"10","author":"H Huang","year":"2010","unstructured":"Huang H, Bhat A, Woodnutt G, Lappe R (2010) Targeting the ANGPT\u2013TIE2 pathway in malignancy. Nat Rev Cancer 10:575\u2013585","journal-title":"Nat Rev Cancer"},{"key":"6485_CR14","doi-asserted-by":"publisher","first-page":"e10666","DOI":"10.15252\/emmm.201910666","volume":"11","author":"JT Regula","year":"2019","unstructured":"Regula JT, Lundh von Leithner P, Foxton R et al (2019) Targeting key angiogenic pathways with a bispecific Cross MA b optimized for neovascular eye diseases. EMBO Mol Med 11:e10666","journal-title":"EMBO Mol Med"},{"key":"6485_CR15","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.15252\/emmm.201505889","volume":"8","author":"JT Regula","year":"2016","unstructured":"Regula JT, Lundh von Leithner P, Foxton R et al (2016) Targeting key angiogenic pathways with a bispecific Cross MA b optimized for neovascular eye diseases. EMBO Mol Med 8:1265\u20131288","journal-title":"EMBO Mol Med"},{"key":"6485_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/IAE.0000000000003003","volume":"41","author":"JS Heier","year":"2021","unstructured":"Heier JS, Singh RP, Wykoff CC et al (2021) The Angiopoietin\/Tie pathway in retinal vascular diseases: a review. Retina 41:1\u201319","journal-title":"Retina"},{"key":"6485_CR17","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40265-022-01713-3","volume":"82","author":"M Shirley","year":"2022","unstructured":"Shirley M (2022) Faricimab: first approval. Drugs 82:825\u2013830","journal-title":"Drugs"},{"key":"6485_CR18","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.3390\/pharmaceutics15051413","volume":"15","author":"L Ferro Desideri","year":"2023","unstructured":"Ferro Desideri L, Traverso CE, Nicol\u00f2 M, Munk MR (2023) Faricimab for the treatment of diabetic macular edema and neovascular age-related macular degeneration. Pharmaceutics 15:1413","journal-title":"Pharmaceutics"},{"key":"6485_CR19","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","volume":"399","author":"CC Wykoff","year":"2022","unstructured":"Wykoff CC, Abreu F, Adamis AP et al (2022) Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. The Lancet 399:741\u2013755","journal-title":"The Lancet"},{"key":"6485_CR20","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Ruiz CQ et al (2022) Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. The Lancet 399:729\u2013740","journal-title":"The Lancet"},{"key":"6485_CR21","doi-asserted-by":"publisher","first-page":"860784","DOI":"10.3389\/fphar.2022.860784","volume":"13","author":"AD Abdin","year":"2022","unstructured":"Abdin AD, Aljundi W, El Jawhari K et al (2022) First year real life experience with intravitreal brolucizumab for treatment of refractory neovascular age-related macular degeneration. Front Pharmacol 13:860784","journal-title":"Front Pharmacol"},{"key":"6485_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40942-021-00349-x","volume":"7","author":"AD Abdin","year":"2021","unstructured":"Abdin AD, Mohamed A, Munteanu C et al (2021) Intravitreal aflibercept following treat and extend protocol versus fixed protocol for treatment of neovascular age-related macular degeneration. Int J Retina Vitreous 7:1\u20135","journal-title":"Int J Retina Vitreous"},{"key":"6485_CR23","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s00417-019-04360-9","volume":"257","author":"AD Abdin","year":"2019","unstructured":"Abdin AD, Suffo S, Asi F et al (2019) Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 257:1671\u20131677","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6485_CR24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s00347-019-0911-5","volume":"117","author":"AD Abdin","year":"2020","unstructured":"Abdin AD, Suffo S, Bischoff-Jung M et al (2020) Advantages of a designated IVI center for a German university eye hospital. Ophthalmologe 117:50\u201357","journal-title":"Ophthalmologe"},{"key":"6485_CR25","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41598-023-27753-7","volume":"13","author":"W Aljundi","year":"2023","unstructured":"Aljundi W, Gradinger F, Langenbucher A et al (2023) Choroidal thickness as a possible predictor of non-response to intravitreal bevacizumab for macular edema after retinal vein occlusion. Sci Rep 13:451","journal-title":"Sci Rep"},{"key":"6485_CR26","doi-asserted-by":"publisher","first-page":"100906","DOI":"10.1016\/j.preteyeres.2020.100906","volume":"82","author":"PS Mettu","year":"2021","unstructured":"Mettu PS, Allingham MJ, Cousins SW (2021) Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities. Prog Retin Eye Res 82:100906","journal-title":"Prog Retin Eye Res"},{"key":"6485_CR27","doi-asserted-by":"publisher","first-page":"e000398","DOI":"10.1136\/bmjophth-2019-000398","volume":"4","author":"S Khanna","year":"2019","unstructured":"Khanna S, Komati R, Eichenbaum DA et al (2019) Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review. BMJ Open Ophthalmol 4:e000398","journal-title":"BMJ Open Ophthalmol"},{"key":"6485_CR28","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.3390\/cells9081869","volume":"9","author":"M Khan","year":"2020","unstructured":"Khan M, Aziz AA, Shafi NA et al (2020) Targeting angiopoietin in retinal vascular diseases: a literature review and summary of clinical trials involving faricimab. Cells 9:1869","journal-title":"Cells"},{"key":"6485_CR29","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.ophtha.2019.03.023","volume":"126","author":"J Sahni","year":"2019","unstructured":"Sahni J, Patel SS, Dugel PU et al (2019) Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial. Ophthalmology 126:1155\u20131170","journal-title":"Ophthalmology"},{"key":"6485_CR30","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1001\/jamaophthalmol.2020.2699","volume":"138","author":"AM Khanani","year":"2020","unstructured":"Khanani AM, Patel SS, Ferrone PJ et al (2020) Efficacy of every four monthly and quarterly dosing of faricimab vs ranibizumab in neovascular age-related macular degeneration: the STAIRWAY phase 2 randomized clinical trial. JAMA Ophthalmol 138:964\u2013972","journal-title":"JAMA Ophthalmol"},{"key":"6485_CR31","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1001\/jamaophthalmol.2020.2685","volume":"138","author":"J Sahni","year":"2020","unstructured":"Sahni J, Dugel PU, Patel SS et al (2020) Safety and efficacy of different doses and regimens of faricimab vs ranibizumab in neovascular age-related macular degeneration: the AVENUE phase 2 randomized clinical trial. JAMA Ophthalmol 138:955\u2013963","journal-title":"JAMA Ophthalmol"},{"key":"6485_CR32","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ophtha.2020.07.060","volume":"128","author":"M Okada","year":"2021","unstructured":"Okada M, Mitchell P, Finger RP et al (2021) Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review. Ophthalmology 128:234\u2013247","journal-title":"Ophthalmology"},{"key":"6485_CR33","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1038\/s41433-023-02553-5","volume":"37","author":"AM Khanani","year":"2023","unstructured":"Khanani AM, Aziz AA, Khan H et al (2023) The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study\u20136 month results. Eye 37:3574\u20133581. https:\/\/doi.org\/10.1038\/s41433-023-02553-5","journal-title":"Eye"},{"key":"6485_CR34","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1159\/000520171","volume":"245","author":"A Foss","year":"2022","unstructured":"Foss A, Rotsos T, Empeslidis T, Chong V (2022) Development of macular atrophy in patients with wet age-related macular degeneration receiving anti-VEGF treatment. Ophthalmologica 245:204\u2013217","journal-title":"Ophthalmologica"},{"key":"6485_CR35","doi-asserted-by":"publisher","first-page":"e757","DOI":"10.1111\/aos.13157","volume":"94","author":"MR Munk","year":"2016","unstructured":"Munk MR, Ceklic L, Ebneter A et al (2016) Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration. Acta Ophthalmol 94:e757\u2013e764","journal-title":"Acta Ophthalmol"},{"key":"6485_CR36","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40123-019-00227-8","volume":"9","author":"M Horani","year":"2020","unstructured":"Horani M, Mahmood S, Aslam TM (2020) A review of macular atrophy of the retinal pigment epithelium in patients with neovascular age-related macular degeneration: what is the link? Part ii. Ophthalmol Ther 9:35\u201375","journal-title":"Ophthalmol Ther"},{"key":"6485_CR37","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40123-019-0177-7","volume":"8","author":"M Horani","year":"2019","unstructured":"Horani M, Mahmood S, Aslam TM (2019) Macular atrophy of the retinal pigment epithelium in patients with neovascular age-related macular degeneration: what is the link? Part I: a review of disease characterization and morphological associations. Ophthalmol Ther 8:235\u2013249","journal-title":"Ophthalmol Ther"},{"key":"6485_CR38","doi-asserted-by":"publisher","unstructured":"Schneider M, Bjerager J, Hodzic-Hadzibegovic D et al (2024) Short-term outcomes of treatment switch to faricimab in patients with aflibercept-resistant neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. https:\/\/doi.org\/10.1007\/s00417-024-06421-0","DOI":"10.1007\/s00417-024-06421-0"},{"key":"6485_CR39","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.oret.2023.08.018","volume":"8","author":"A Szigiato","year":"2024","unstructured":"Szigiato A, Mohan N, Talcott KE et al (2024) Short-term outcomes of faricimab in patients with neovascular age-related macular degeneration on prior anti-VEGF therapy. Ophthalmol Retina 8:10\u201317","journal-title":"Ophthalmol Retina"},{"key":"6485_CR40","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1007\/s00417-023-06116-y","volume":"261","author":"H Matsumoto","year":"2023","unstructured":"Matsumoto H, Hoshino J, Nakamura K et al (2023) Short-term outcomes of intravitreal faricimab for treatment-na\u00efve neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 261:2945\u20132952","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6485_CR41","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1007\/s00417-020-04730-8","volume":"258","author":"L-M Marquis","year":"2020","unstructured":"Marquis L-M, Mantel I (2020) Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 258:1591\u20131596","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6485_CR42","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1136\/bjophthalmol-2019-314251","volume":"104","author":"RP Gale","year":"2020","unstructured":"Gale RP, Pearce I, Eter N et al (2020) Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study. Br J Ophthalmol 104:493\u2013499","journal-title":"Br J Ophthalmol"},{"key":"6485_CR43","first-page":"2695","volume":"260","author":"FG Holz","year":"2022","unstructured":"Holz FG, Schmitz-Valckenberg S, Wolf A et al (2022) A randomized, open-label, multicenter study of switching to brolucizumab with or without a loading dose for patients with suboptimal anatomically controlled neovascular age-related macular degeneration\u2014the FALCON study. Graefes Arch Clin Exp Ophthalmol 260:2695\u20132702","journal-title":"Graefes Arch Clin Exp Ophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-024-06485-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-024-06485-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-024-06485-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T14:11:43Z","timestamp":1725545503000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-024-06485-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,12]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["6485"],"URL":"https:\/\/doi.org\/10.1007\/s00417-024-06485-y","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,12]]},"assertion":[{"value":"16 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were reviewed and approved by Ethics Committee of the Medical Association of Saarland, Germany (<i>Nr. 123\/20<\/i>) and in accordance with the 1964 Helsinki declaration, as well as its later amendments. This article does not contain any studies with animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"An informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Alaa Din Abdin has received speaker and consultant honoraria from Novartis and Bayer Company. All other authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest regarding this research topic.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure of potential conflicts of interest"}}]}}